Bariatric surgery may reduce heart failure risk

American Heart Association Meeting Report – Poster: M2019 – Session: LF.APS.P138

November 14, 2016 Categories: Heart News, Scientific Conferences & Meetings

Study Highlights:

  • Bariatric surgery and other treatments that cause substantial weight loss can significantly reduce the risk of heart failure in obese patients.
  • Bariatric surgery patients had a much lower risk of heart failure than patients who did lifestyle modifications involving severe dieting and regular exercise.
  • Reduced risk of heart failure may be due to bariatric surgery’s effects on other risk factors of heart failure, including diabetes, hypertension and atrial fibrillation.

Embargoed until 10:45 a.m. CT/11:45 a.m. ET, Monday, Nov. 14, 2016

NEW ORLEANS, Nov. 14, 2016 — Bariatric surgery and other treatments that cause substantial weight loss can significantly reduce the risk of heart failure in obese patients, according to preliminary research presented at the American Heart Association’s Scientific Sessions 2016.

Researchers compared 25,804 bariatric surgery patients in a Scandinavian obesity surgery registry to 13,701 Swedish nationwide registry patients who used an intensive structured lifestyle-modification program. Both groups had no history of heart failure before starting treatment and body mass indices greater than 30 and weighed on average 119 kilograms/262.35 pounds before treatment.

They found:

  • 4 years after start of treatment, the risk of heart failure was nearly 50 percent lower in the bariatric surgery group.

  • The rate of death and heart attack was similar between the treatment groups.

  • However, patients in the bariatric surgery group had fewer incidences of atrial fibrillation, diabetes and hypertension.

  • The bariatric surgery group lost more weight than those in the intensive lifestyle modification program. Obesity surgery led to 18.8 kilograms/41.44 pounds more weight loss than lifestyle treatment after one year, and 22.6 kilograms/49.82 pounds more weight loss after two years.

The lifestyle modification program participants consumed a very low-energy diet of 500 calories a day for 3 to 10 weeks followed by 2 to 8 weeks of gradual incorporation of food, and then 9 months of a weight-maintenance regimen that included regular exercise, dietary advice and behavioral therapy. Around 20 percent of patients in the lifestyle modification program dropped out by the first year.

“Our study shows an association between obesity and heart failure and offers support for efforts to prevent and treat obesity aggressively, including the use of bariatric surgery,” said Johan Sundstrom, M.D., Ph.D., senior author of the study and professor of epidemiology at Uppsala University in Sweden. “Bariatric surgery might affect the incidence of atrial fibrillation, diabetes and hypertension — known risk factors of heart failure — explaining the lower risk of heart failure we observed.”

While the findings report that heart failure risk is lower in patients who lose more weight, it does not prove that obesity causes heart failure, he said. But, patients in both treatment groups lost weight intentionally, supporting the idea.

The study was done in a most likely white Scandinavian population. Whether the study’s findings would relate to a U.S. population is unclear. In addition, because the study’s participants did not have heart failure before the weight-loss treatment, “the study does not provide any advice on how to treat cardiovascular disease in obese patients,” Sundstrom said.

American Heart Association, American College of Cardiology and the Obesity Society Clinical Practice guidelines advise adults with a body mass index (BMI) of 40 or higher and patients with a BMI of 35 or higher, who have two other cardiovascular risk factors such as diabetes or high blood pressure, that bariatric surgery may provide significant health benefits. The guidelines do not recommend weight loss surgery for people with a BMI under 35 and do not recommend one surgical procedure over another.

Co-authors are Gustaf Bruze, Ph.D.; Johan Ottosson, M.D., Ph.D.; Claude Marcus, M.D., Ph.D.; Ingmar Näslund, M.D., Ph.D.; and Martin Neovius, Ph.D. Author disclosures are on the abstract.

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases, Uppsala University, Karolinska Institute, and the Swedish Research Council.

Note: Scientific presentation time is 10:45 a.m. CT on Monday, Nov. 14, in the Science and Technology Hall, Population Science Section.

Additional Resources:

###

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

For Media Inquiries and AHA Spokesperson Perspective:

AHA News Media in Dallas: (214) 706-1173

AHA News Media Office, Nov. 12-16, 2016 at the Ernest N. Morial Convention Center: (504) 670-5106

For Public Inquiries: (800) AHA-USA1 (242-8721)

heart.org and strokeassociation.org

Life is why, science is how . . . we help people live longer, healthier lives.